Biowaiver monographs for immediate release solid oral dosage forms: prednisolone.

2.50
Hdl Handle:
http://hdl.handle.net/10029/8419
Title:
Biowaiver monographs for immediate release solid oral dosage forms: prednisolone.
Authors:
Vogt, M; Derendorf, H; Krämer, J; Junginger, H E; Midha, K K; Shah, V P; Stavchansky, S; Dressman, J B; Barends, D M
Abstract:
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisolone are reviewed. Data on its solubility, oral absorption, and permeability are not totally conclusive, but strongly suggest a BCS Class 1 classification. Prednisolone's therapeutic indications and therapeutic index, pharmacokinetics, and the possibility of excipient interactions were also taken into consideration. Available evidence indicates that a biowaiver for IR solid oral dosage forms formulated with the excipients tabulated in this article would be unlikely to expose patients to undue risks.
Citation:
J Pharm Sci 2007, 96(1):27-37
Issue Date:
1-Jan-2007
URI:
http://hdl.handle.net/10029/8419
DOI:
10.1002/jps.20768
PubMed ID:
17039494
Type:
Article
Language:
en
ISSN:
0022-3549
Appears in Collections:
Miscellaneous

Full metadata record

DC FieldValue Language
dc.contributor.authorVogt, M-
dc.contributor.authorDerendorf, H-
dc.contributor.authorKrämer, J-
dc.contributor.authorJunginger, H E-
dc.contributor.authorMidha, K K-
dc.contributor.authorShah, V P-
dc.contributor.authorStavchansky, S-
dc.contributor.authorDressman, J B-
dc.contributor.authorBarends, D M-
dc.date.accessioned2007-02-15T11:14:46Z-
dc.date.available2007-02-15T11:14:46Z-
dc.date.issued2007-01-01-
dc.identifier.citationJ Pharm Sci 2007, 96(1):27-37en
dc.identifier.issn0022-3549-
dc.identifier.pmid17039494-
dc.identifier.doi10.1002/jps.20768-
dc.identifier.urihttp://hdl.handle.net/10029/8419-
dc.description.abstractLiterature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisolone are reviewed. Data on its solubility, oral absorption, and permeability are not totally conclusive, but strongly suggest a BCS Class 1 classification. Prednisolone's therapeutic indications and therapeutic index, pharmacokinetics, and the possibility of excipient interactions were also taken into consideration. Available evidence indicates that a biowaiver for IR solid oral dosage forms formulated with the excipients tabulated in this article would be unlikely to expose patients to undue risks.en
dc.format.extent126318 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen
dc.titleBiowaiver monographs for immediate release solid oral dosage forms: prednisolone.en
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.